Loading stock data…
$3.52-0.07 (-1.95%)
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States.
Nephros, Inc. in the Healthcare sector is trading at $3.52 with a market capitalization of $47M. Wall Street consensus targets $6.25 (3 analysts), implying a +77.6% move over the next 12 months. The stock is currently 45% below its 52-week high of $6.42, remaining 6.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.02M↑ | $5.21M↑ | $4.73M↓ | $4.76M↑ | $4.42M |
| Gross Profit | $4.03M↑ | $2.99M↑ | $2.76M↓ | $2.92M↑ | $2.79M |
| Operating Income | $1.21M↑ | $97,000↑ | $18,000↓ | $314,000↑ | $248,000 |
| Net Income | $1.20M↑ | $140,000↑ | $62,000↓ | $337,000↑ | $237,000 |
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological ...